Vuzix Schedules Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Business Update
Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses, waveguides and augmented reality (AR) technology, is pleased to announce that the Company will host a conference call regarding its fourth quarter and full year 2024 operating results on Thursday,
TWFG Announces Unaudited Preliminary Fourth Quarter and Full Year 2024 Financial Results
A reconciliation of Organic Revenue Growth Rate to total revenue growth rate, the most directly comparable financial measure, is outlined in the reconciliation table accompanying this release. TWFG expects to release its full fourth quarter and full-year 2024 results mid-March followed by a conference call and webcast to discuss these results.
Medpage Today on MSN3d
Melatonin's Anti-Cancer Potential; Prenatal PFAS and Cancer; Anti-Viral Gel for HPVPrenatal exposure to per- and polyfluoroalkyl substances (PFAS), so-called forever chemicals, in drinking water had ...
Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response ...
Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...
Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...
Nath had previously used pembrolizumab in a small study to treat people with a brain infection called progressive ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
Hosted on MSN4d
Cancer treatment costs: 'I had to rob money from the money we’d set aside for my son’s wedding'Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, ...
Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback